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Autistic featuresAbstract Background: Rett syndrome is a progressive neurodevelopment disorder which mainly
affects females and is a common cause of mental retardation. Loss of purposeful hand movements,
regression of acquired cognitive and motor skills and autistic features are the main criteria associ-
ated with this disorder. Sixty to ninety percent of the cases show MECP2 gene mutations, which
reside on the X chromosome. MECP2 regulates gene expression in a repressive manner.
The aim of this study is to estimate the incidence of MECP2 mutations in 32 female Egyptian
patients clinically diagnosed with Rett syndrome, and to correlate their clinical features with
MECP2 mutation status.
Patients: 32 female Egyptian patients with a mean age of 36.9 months diagnosed clinically to suffer
from Rett syndrome are the cohort of this study.
Methods: Thorough clinical examination, MRI, EEG and testing for MECP2 gene mutations.
Results: Twenty of the 32 (62.5%) patients showed MECP2 mutations an incidence which falls
within that reported in the literature. Patients with MECP2 gene mutations presented with more
severe clinical abnormalities.
Conclusions: Mutation screening for MECP2 is a fast and reliable method to diagnose patients
clinically suspected to suffer from Rett syndrome or female patients with atypical Rett syndrome
features, mental retardation, developmental delay and other neurological abnormalities who do
not ﬁt any speciﬁc diagnosis. Also, patients with MECP2 mutation presented with a more severe
phenotype.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Rett syndrome is a progressive neurodevelopmental disorder
and one of the most common causes of mental retardation
in females, affecting approximately 1 in every 10,000–
15,000 females worldwide.1 Patients with classic Rett
26 H. Megahed et al.syndrome appear to develop normally until 6–18 months of
age then gradually lose purposeful hand movements. This
phase is followed by regression of the acquired cognitive
and motor skills, autistic tendencies and gait apraxia.
Eventually the condition becomes stationary. Concurrent
manifestations may include episodes of apnea, hypercapnia,
and seizures.2
The majority of cases result from heterozygous mutations
in theMECP2 gene, the possibility of detecting such mutations
in patients with Rett syndrome has changed the face of this
unique disorder. MECP2 gene is located on the long arm of
chromosome X (Xq 28) and encodes for the methyl-CpG bind-
ing protein 2, which is a ubiquitous transcriptional repressor.
This protein functions by selectively binding methyl C-pG
islands in the mammalian genome and regulates gene expres-
sion, mainly in a repressive manner.3
MECP2 protein regulates genes involved in brain function,
although the protein is found through-out the body. Within
the brain, this protein is vital for the function of neurons.
MECP2 has a role in maintaining synapses between the neu-
rons, allowing cell-to-cell communications to take place. The
MECP2 protein also participates in processing messenger
RNA (mRNA), which serves as genetic blueprints for making
proteins. MECP2 controls a process known as alternative
splicing, which controls the production of different versions
of certain proteins. This process is crucial for normal commu-
nication between neurons in the brain.4
MECP2 is a member of a family of nuclear protein and is
characterized by the presence of a methyl C-pG binding
domain (MBD). These proteins are capable of binding
speciﬁcally to methylated DNA. Methylation is a major
modiﬁcation of the eukaryotic genome essential for the process
of mammalian development. Binding of MECP2 gene to the
methylated gene-promoter DNA of certain genes results in
transcriptional repression of these genes.5
Mutations in MECP2 may be sporadic or germ line
mutations. Alternatively, Rett syndrome may be caused by
mutations in CDKL5 or FOXG1 genes in 10% of cases.
Sporadic cases constitute up to 95% of cases with MECP2
mutations. The parents in this situation are genotypically nor-
mal and the mutated MECP2 is usually thought to be derived
from the normal male copy of the X chromosome. However,
the reason behind the sperm to mutate is not yet fully known.
On the other hand, germ line mutations are inherited from
phenotypical normal females, to her offspring.6
The aim of this work is to study the incidence of MECP2
mutation in a cohort of 32 Egyptian female patients withTable 1 Speciﬁc DNA primers used to amplify exons 3 and 4 of M
Exon Fragment Primers
3 3.1F 50-AAG ATC TGA GTG TAT GA
3.1R 50-TTT GCT TAA GCT TCC GTG
3.2F 50-AAG AGA AAG AGG GCA A
3.2R 50-AAG CAC ACC TGG TCT CA
4 4.1F 50-CAG TTT GTC AGA GCG TT
4.1R 50-TGA CGG AGT ACG GTC TC
4.2F 50-CAG TTC CTG GGA AGC TC
4.2R 50-TGA CTC CTC TGG GCA TC
4.3F 5-CAG TGG GAA AGG ACT GA
4.3R 5-TGA CCA GTT AAT CGG GARett syndrome and to compare their clinical features with
MECP2 mutation status.2. Patients and methods
2.1. Patients
This is a retrospective study carried out on a cohort of thirty-
two female Egyptian patients diagnosed clinically to suffer
from Rett syndrome according to the classic criteria of this
syndrome.7 Their ages ranged from 18 months to 56 months
with a mean age of 36.9 months. A written consent was
obtained from the patient’s guardians.
2.2. Methods
All patients were subjected to a thorough clinical examination.
The presence, at time of diagnosis, of psychomotor retarda-
tion, stereotyped hand movement, microcephaly and epilepsy
were recorded. We also assessed the presence of regression of
the acquired milestones in the form of loss of sitting, standing
and walking as well as loss of speech. Neuro-imaging in the
form of MRI of the brain and electro-encephalographic
(EEG) tracing were performed to all cases.
All patients underwent DNA extraction from their periph-
eral blood leukocytes using the Qiagen QIAampDNAMaxi
extraction kit as protocol.
DNAyield and quality were determined using theNanoDrop
ND-100 spectrophotometer (Nanodrop Technologies, USA).
The protocol of measuring DNA concentration by spectropho-
tometer is reviewed by Sambrook and Russell.8
DNA was PCR ampliﬁed using the GeneAmp PCR system
9700 thermocycler (Applied Biosystems, UK) using the follow-
ing PCR program: 95 C for 10 min, followed by 40 cycles of
95 C for 1 min, the optimal annealing temperature for the
speciﬁc primers, for 1 min and 72 C for 1 min. On ﬁnal exten-
sion step for 7 min at 72 C was then performed, followed by a
holding step at 4 C. The speciﬁc primers used are listed in
Table 1 and it ampliﬁes exons 3 and 4 of MECP2 gene in 5
overlapping fragments (3.1, 3.2, 4.1, 4.2, and 4.3). This was fol-
lowed by analysis of the PCR products using agarose gel elec-
trophoresis. Details of protocol for agarose gel electrophoresis
are available in Sambrook and Russell.8
PCR products were puriﬁed using Invetrogen puriﬁcation
kit (Purelink Nucleic Acid Puriﬁcation Rack) (Invetrogen
Llt., UK) according to the manufacturer’s instruction.ECP2 gene.
Product size Tm (C)
T GGC CTGGG-30 428 bp 60
TCC AGC-30 60
GC ATG AGC-30 405 bp 60
G TGT TCA-30 60
G TCA CCA CCA T-30 626 bp 62
C TGC ACA ACA GAT-30
C TTC TCA AGA T-30 616 bp 62
T TCC CTC TTT-30
A GAC CTG TAA G-3
00
566 bp 60
A GCT TTG TCA G-3
00
60
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sequenced and analysed for mutations by direct sequencing
in both directions using Big Dye Direct Cycle Sequencing
Kit using ABI PRISM 3100 Genetic Analyser (Applied
Biosystems) according to manufacturer’s protocol and
analysed using the SeqScape software (Applied Biosystems).
3. Results
We studied the MECP2 mutations in 32 Egyptian female
patients diagnosed clinically as Rett syndrome. The incidence
of the following clinical abnormalities (psychomotor retarda-
tion, stereotyped hand movement, microcephaly, epilepsy,
regression of the acquired milestones in the form of loss of
sitting, standing and walking as well as loss of speech and
respiratory rhythm abnormalities) were recorded in this cohort
of 32 patients.
Twenty cases showed mutations in MECP2 coding region
using direct sequencing and 12 cases were wild type for the
gene as shown in Fig. 1. This revealed a mutation incidence
of 62.5%.
The incidence of the clinical abnormality found and muta-
tions inMECP2 gene and its nucleotide changes in this cohort
of 32 Egyptian female patients are illustrated in Table 2.
Within our cohort there were 24 patients with epilepsy (24/
32) (75%). The age of onset of epilepsy ranged from 20 to
56 months with a mean age of 38.3 months. Seizures wereFigure 1 Chromatograph demonstrating heterozygous muta-
tions in MECP2 gene. The nucleotide change (A>A/G) was seen
by direct sequencing in the forward (A) and the reverse (B)
directions.classiﬁed according to the criteria of the International
League Against Epilepsy (ILAE).9 Data concerning the
semiology of seizures at the onset showed generalized clonic
tonic (GCT) waves in 8 cases, while 6 cases had complex par-
tial seizures and 10 cases had both. Also, MRI changes of the
brain were present in 24/32 cases including widening of the
subarachnoid spaces, mild ventriculomegaly and dysmyelina-
tion. Eighteen out of 24 of the epileptic patients had MECP2
mutations (75%), while only 6/24 were wild type for
MECP2. Microcephaly was present in 26/32 (81.2%) of all
cases and was found in 20/24 (83.3%) of the epileptic cases.
Out of the 26 microcephalic patients 16 showed mutations
and 10 cases were wild type.
Regarding their developmental milestones, 4/32 lost their
sitting ability before the age of 2 years, while 12/32 lost ability
to stand and 21/32 could not walk unsupported. Speech was
lost in 24/32 cases, while only 8 cases preserved their speech.
Out of these 8 cases only 3 showed MECP2 mutations.
A statistically signiﬁcant correlation is found between
mutations in MECP2 gene and the clinical ﬁnding of psy-
chomotor regression (100%), stereotype hand movement
(p= 0.03), epilepsy (p= 0.018), loss of ability to stand
(p= 0.01) and rhythmic respiratory problems (p= 0.003).
Although the correlation between the remaining 4 clinical cri-
teria (microcephaly, ability to sit and to walk and ability to
speak) andMECP2 gene mutations did not reach a statistically
signiﬁcant value yet, the cases with these clinical abnormalities
showed higher incidence in cases showing MECP2 gene muta-
tions (Table 3 and Figs. 2–4). The statistical analysis for calcu-
lating ‘‘p’’ value was performed using Fisher’s exact test and
Likelihood ratio tests (as appropriate to the data). Table 3
demonstrates the statistical correlation between these clinical
abnormalities and mutations in theMECP2 gene in this cohort
of 32 patients.
All statistical analyses were done using the Statistical
Package for the Social Science (SPSS) version 16. The results
were considered statistically signiﬁcant if the p value is 60.05.
4. Discussion
The incidence of mutation inMECP2 gene for classic Rett syn-
drome ranges between 60% and 90%.5 The wild range of
mutation detection can be attributed to both the stringency
of the clinical selection criteria for diagnosis as well as the type
of diagnostic molecular analysis undertaken. The diagnostic
criteria for Rett syndrome have been widened to include the
presence of psychomotor regression, which increases the num-
ber of patients potentially included within the classic Rett
category.7 In this study, the mutation rate is 62.5%, which falls
within this range.
Our results revealed the presence of missense mutations
resulting from single base substitution mutation in exon 4,
which is the mutation hot spot of MECP2. This mutation
which is associated with the full spectrum of Rett syndrome
abolishes the function of the putative MECP2 protein and
inhibits its binding to the heterochromatin through the
MBD, which in turn prohibits downstream functions like
nucleosome-nucleosome interaction and ﬁnal chromatin con-
densation.3 Females, who harbour mutations, which cause loss
of gene function, would be expected to show the most severe
phenotype. These patients were never been able to sit, or walk
Table 2 Master table showing all clinical and molecular criteria seen in our cohort of 32 Egyptian female patients.
Case No. Nucleotide
changes
Age at
diagnosis
in month
Psychomotor
retardation
Stereotyped
hand
movement
Microcephaly Epilepsy Loss of Loss of
speech
Resp. rhythm
problem
Sitting Stand Walk
1 203 C>T 52 +  + +    + 
2 383 A/AG 38 + + + +  + + + +
3 69 C>T 48 + + + +  + +  +
4 203 C>T 18 +    + + + + +
5 WT 32 +  + +    + 
6 69 C>T 42 + + + +  + + + 
7 69 C>T 50 + + + +  + +  +
8 383G>A/G 45 +  + +  + + + 
9 WT 24 +   +  + + + 
10 69 C>T 44 + + + +   + + 
11 203 C>T 22 + +   + + + + 
12 203 C>T 32 +  + +    + 
13 WT 51 + + + +   +  
14 69 C>T 40 +  + +    + +
15 WT 33 +   +    + 
16 WT 29 +  +     + 
17 205 C>T 52 + + + +  + +  +
18 WT 33 + + +     + 
19 203 C>T 27 + + + +    + +
20 383 C/AG 20 + + + + + + + + 
21 203 C>T 42 + +  +    + 
22 203 C>T 22 +  + + + + + + 
23 WT 32 +  +    + + 
24 WT 48 +  + +   +  
25 WT 36 + + +      
26 205 C>T 57 + + + +   + + +
27 263 C>T 33 + +  +  + + + +
28 WT 37 +  +      
29 205 C>T 50 + + + +   + + +
30 WT 45 +  + +   +  
31 WT 52 +  +    + + 
32 69 C>T 20 +  + +   + + 
28 H. Megahed et al.and have no expressive speech. At the other end of the
spectrum are patients with mild form of the disease who do
not harbour mutations in the MECP2 hotspot or patients
who carry missense mutations, which lie out-side the known
functionally vital domain.10
It would be expected that females who harbour the same
mutations to present with similar clinical features and severity
of the disease, however in our study this was not the case,
which is in accordance with Huppke et al.11, who demonstrat-
ed that several female patients with the same mutations
displayed different phenotypes of the disease, which indicate
that additional or other factors inﬂuence the clinical picture
and severity of Rett syndrome, besides the type or position
of the mutation.
Since it is an X-linked disorder only females were thought
to be affected while the condition was considered lethal in
males. However, a reasonable number of affected males, with
varying disease phenotype, have been reported in recent years
indicating that MECP2 mutations are responsible for some
cases of mental retardation in males.12
MECP2 comprises 4 exons and has 2 isoforms as a result of
using 2 alternative start codons and alternative splicing of exon
2. Exon 1 contributes to approximately 0.5% of the overall
mutations and occurs only in females. No mutations have been
observed within our cohort in exon 2. Exons 3 and 4 harbourthe majority of causative mutations. Exons 3 and 4 encode the
MECP2 functional domains, the Methyl Binding Domain
(MBD) and Transcriptional Repression Domain (TRD)
respectively. The TRD constitutes the nuclear localization
signal (NLS) which is important for translocation of newly
synthesized MECP2 from the cytoplasm to the nucleus.
Mutations in MECP2 coding exons are found in 80–90% of
patients and are present mostly in the MECP2 functional
domains therefore, this study assessed exons 3 and 4 of the
MECP2 gene.
Most mutations are single nucleotide substitutions and
small insertions and deletions. The eight most common recur-
rent point mutations include missense and nonsense mutations
accounting for more than half of all the Rett cases with iden-
tiﬁed deletions.MECP2 is also prone to large rearrangements,
such as duplications and deletions of the whole exons, mainly
involving exons 3 and 413 or even the entire gene.5
Mutations in the MECP2 gene may result in several
disorders including Rett syndrome, MECP2 duplication syn-
drome, MECP2-related severe neonatal encephalopathy,
PPM-X syndrome, as well as other disorders of moderate to
severe X-linked intellectual disabilities. A number of cases with
features of Rett syndrome and signs and symptoms mimicking
Angelman syndrome have been reported, where MECP2
mutations were present.12
Table 3 Statistical correlation between incidence of the clinical abnormalities and mutation in MECP2 gene and their relevant p
value. A statistically signiﬁcant correlation (p 6 0.05) in bold found between mutation in MECP2 gene and psychomotor retardation,
epilepsy, inability to stand and respiratory rhythmic problems.
Clinical and molecular ﬁndings MECP2 mutation Wild type p value
Total number of cases 32 cases
Psychomotor regression 32 20 12
Stereotypic hand movement
Present 16 (50%) 13 3 0.033
Absent 16 7 9
Microcephaly
Present 26 (81.3%) 16 10 0.66
Absent 6 4 2
Epilepsy
Present 24 (75%) 18 6 0.018
Absent 2 6
Ability to sit
Loss of sitting 4 (12.5%) 4 0 0.14
Can sit 28 16 12
Ability of standing
Loss of standing 12 (37.5%) 11 1 0.009
Can stand 20 9 11
Ability of walking
Loss of walking 21 (65.6%) 15 6 0.145
Can walk 11 5 6
Ability to speak
Loss of speech 24 (75%) 17 7 0.104
Can speak 8 3 5
Respiratory rhythmic problems
Present 10 (31.3%) 10 0 0.003
Absent 22 10 12
Figure 3 Clinical abnormalities in 20 patients with Rett
syndrome having MECP2 gene mutation. Positive = Clinical
abnormality exist, Negative = No clinical abnormality.
Figure 2 Clinical abnormalities in 32 patients with Rett
syndrome, comparison between cases with positive and negative
(wild type) MECP2 mutations.
Correlation between clinical features and MECP2 gene mutations in Rett syndrome patients 29In addition to the classic form of Rett syndrome, several
atypical forms have been identiﬁed and include 3 main sub-
types. The congenital variant (Rolando variant) is a severe
subtype, where the patients’ development and head circumfer-
ence are abnormal since birth. The typical gaze of Rettsyndrome is usually absent in this subtype. Another atypical
subtype is the preserved speech (Zappella variant), where
patients acquire a few manual skills and their language usually
recovers after the regression phase when they are about 5 years
of age. The head circumference, height and weight are usually
Figure 4 Clinical abnormalities in 12 patients with Rett
syndrome andMECP2 wild type. Positive = Clinical abnormality
exist, Negative = No clinical abnormality.
30 H. Megahed et al.within normal. This variant represents a mild phenotype of the
disease. The 3rd described atypical variant of Rett syndrome is
Haneﬁeld or early epilepsy variant, where seizures occur before
the patients reach the age of 5 years.2 In our cohort, 24 cases
developed epilepsy before the age of 5 years (75%). Out of
those 24 cases 18 patients (75%) showed MECP2 mutations.
Also, within our cohort, 8 cases had preserved speech (25%)
within whom, 3 cases showed MECP2 mutations.
In our study, the more severe impairment of hand use and
the earlier onset of respiratory rhythm dysfunction were asso-
ciated with MECP2 mutations, which is in accordance with
reports by Downs et al.14 and Psoni et al.12
The incidence of epilepsy among our cases was 81.3%,
which is in agreement with other reports.15 Microcephaly
was present in most of the cases with epilepsy 20/24 (83.3%),
and was more frequent among patients with generalized ton-
ic-clonic cases. Sixteen, out of the 26 microcephalic patients
(61.5%), showed MECP2 mutations. This is in contrast with
the ﬁndings by Glaze et al.16 who found no correlation
between MECP2 mutations and either the presence or the
severity of epilepsy.
No correlation was noted amongst the various groups
regarding the brain MRI and EEG ﬁndings, which is similar
to the results by Ponsi et al.12 However, in females with
MECP2 mutations the non speciﬁc neuro-imaging ﬁndings
may reﬂect the absolute volumic brain reduction due to late
neuronal maturation and delayed dendritic arborization result-
ing clinically in microcephaly as described by Mahmood
et al.175. Conclusions
– Our study for 32 female Egyptian patients with Rett
syndrome revealed MECP2 gene mutation in 20 cases an
incidence of 62.5%.
– Mutation screening for MECP2 using direct sequencing
technique is a fast and reliable method to diagnose patients
clinically suspected to suffer from Rett syndrome.– Patients with Rett syndrome display a more severe pheno-
type when MECP2 mutation is present compared to
patients with wild type MECP2 or mutations outside the
common known mutation hot spot.
– The spectrum of Rett syndrome is independent of the type
and locus of MECP2 mutations.
– Direct DNA sequencing of MECP2 may be particularly
useful and important to diagnose and conﬁrm Rett syn-
drome in patients with atypical forms of the disease.
– Also, this study provides the basis for clinical and genetic
counselling for the families of patients with Rett syndrome.
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